Clinical trials: Stage II Breast Cancer
Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
This randomized phase III trial studies two different schedules of zoledronic acid to compare how well they work in reducing bone-related complications in patients with breast cancer, prostate cancer, or multiple myeloma that has…
- Conditions
- Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone
- Trial name
- NCT00869206
- Testing
- zoledronic acid
- Where
- 504 sites in United States, Puerto Rico
- Volunteers
- 1,822 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Breast Cancer
Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
Trastuzumab or Herceptin is an antibody directed against Her-2. Her-2 is a growth factor receptor which is present on the tumors of 25% of patients with breast cancer.
- Trial name
- NCT00169104
- Testing
- G-CSF, trastuzumab, vinorelbine
- Volunteers
- 23 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer
Xeloda (Capecitabine) and External Beam Radiation
The goal of this clinical research study is to find out if Xeloda® (capecitabine) and radiation therapy can help to control breast cancer that did not respond well to chemotherapy.
- Trial name
- NCT00916578
- Testing
- Radiation Therapy, Capecitabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Vaginal Atrophy
A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting
This is a phase II, prospective, randomized, double-blind, placebo-controlled, international (Spain and Sweden) and multicentre study to explore the safety of 0.005% estriol vaginal gel in women with early stage breast cancer in…
- Trial name
- BLISSAFE (NCT02413008)
- Testing
- estriol
- Where
- 6 sites in Spain, Sweden
- Volunteers
- 61 people
- Sponsor
- ITF Research Pharma, S.L.U.
HER-2 Positive Metastatic Breast Cancer
Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer
This study is for women and men who have previously treated metastatic (has spread to other parts in the body), Her2- positive breast cancer.
- Trial name
- NCT00810017
- Testing
- Etoposide, Trastuzumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Medstar Health Research Institute
Fallopian Tube Carcinoma, Ovarian Endometrioid Adenocarcinoma
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
This partially randomized phase I/II trial studies the side effects and the best dose of cediranib maleate and olaparib and to see how well they work compared to olaparib alone in treating patients with ovarian, fallopian tube…
- Conditions
- Fallopian Tube Carcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Serous Adenocarcinoma
- Trial name
- NCT01116648
- Testing
- Biopsy Procedure, Biospecimen Collection, Cediranib Maleate
- Where
- 14 sites in United States
- Volunteers
- 155 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming…
- Trial name
- NCT00088985
- Testing
- therapeutic autologous dendritic cells, trastuzumab, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
This phase II trial studies how well giving paclitaxel albumin-stabilized nanoparticle (Nab-paclitaxel) formulation together with bevacizumab followed by bevacizumab and erlotinib hydrochloride work in treating patients with…
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00733408
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, erlotinib hydrochloride
- Where
- 17 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of Washington
Breast Cancer
Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)
This is a phase II one arm study. Patients with HER2 (Human Epidermal Growth Factor Receptor 2)positive early stage breast cancer will receive ABI-007 and vinorelbine in combination with trastuzumab before having breast surgery.
- Trial name
- NCT00503750
- Testing
- Pre operativeTrastuzumab, ABI-007 (Abraxane), Vinorelbine
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Emory University
Breast Cancer
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
The purpose of this research study is to : Determine how effective cisplatin or carboplatin is in slowing the time it takes for ER negative (estrogen-receptor-negative), PR negative (progesterone receptor-negative), HER2 negative…
- Trial name
- NCT00483223
- Testing
- Cisplatin, carboplatin
- Where
- 10 sites in United States
- Volunteers
- 86 people
- Sponsor
- Massachusetts General Hospital
Metastatic Breast Cancer
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab
This was a multi-institutional, multinational, open-label, single-arm Phase Ib/II study designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of trastuzumab emtansine (trastuzumab-MCC-DM1) administered by…
- Trial name
- NCT00875979
- Testing
- Trastuzumab emtansine [Kadcyla] 3.0 mg/kg, Trastuzumab emtansine [Kadcyla] 3.6 mg/kg, Pertuzumab 420 mg
- Where
- 20 sites in United States, Belgium and 5 more
- Volunteers
- 67 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Stage II Breast Cancer
Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
This phase II trial studies how well exemestane before surgery works in treating postmenopausal patients with newly diagnosed estrogen receptor positive stage II-III breast cancer.
- Conditions
- Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT01831076
- Testing
- Exemestane, Exemestane and tamoxifen
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Colorado, Denver
Breast Cancer
Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer
This protocol seeks to build on the favorable results of the investigators' phase I trial (Pro00015617) by extending the findings to a larger cohort of subjects.In this study, the investigators hypothesize that 21Gy (Gray) as a…
- Trial name
- NCT02482376
- Testing
- Stereotactic body radiotherapy ( SBRT)
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Duke University
Breast Neoplasms
Mammosite Breast Brachytherapy Optimization in the Treatment of Breast Carcinoma
The purpose of this study is to determine if Mammosite Catheter optimization using multiple dwell position delivery decreases skin toxicity over historically reported skin toxicity with the single dwell delivery method.
- Trial name
- Mammosite (NCT00611624)
- Testing
- Mammosite brachytherapy radiation
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Yale University
Lymphedema
Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection
This randomized phase III trial studies how well education with or without physical therapy intervention works in preventing lymphedema in women with stage I, II, or III breast cancer who are undergoing axillary lymph node…
- Trial name
- NCT00376597
- Testing
- quality of life assessment, educational intervention, Physical therapy
- Where
- 76 sites in United States
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer
This phase II trial studies how well everolimus with or without trastuzumab works in treating patients with breast cancer that has not responded to hormone therapy and has spread from where it started to other places in the body.
- Trial name
- NCT00912340
- Testing
- Everolimus, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Emory University
Breast Cancer, Radiation Toxicity
Lovastatin in Reducing Side Effects After Radiation Therapy in Women With Breast Cancer
RATIONALE: Drugs, such as lovastatin, may protect normal cells from the side effects of radiation therapy. PURPOSE: This phase II trial is studying how well lovastatin works in reducing side effects after radiation therapy in…
- Trial name
- NCT00902668
- Testing
- lovastatin, questionnaire administration, adjuvant therapy
- Volunteers
- 3 people
- Sponsor
- Virginia Commonwealth University
Metastatic Breast Cancer
Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
The purpose of this study is to determine the ORR associated with Doxil in combination with carboplatin in HER2- (negative) MBC (and with Herceptin in HER2+ MBC).
- Trial name
- NCT00303108
- Testing
- Pegylated liposomal doxorubicin, Carboplatin, trastuzumab
- Where
- 57 sites in United States
- Volunteers
- 136 people
- Sponsor
- US Oncology Research
Breast Cancer, Cancer
A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer
A randomized multi-arm study evaluating the safety and efficacy of palbociclib and anastrozole with or without nivolumab in participants with ER+/HER2- breast cancer
- Trial name
- CheckMate 7A8 (NCT04075604)
- Testing
- Nivolumab, Anastrozole, Palbociclib
- Where
- 36 sites in United States, Australia and 6 more
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer
Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00824538
- Testing
- sunitinib malate, flow cytometry, immunohistochemistry staining method
- Volunteers
- 13 people
- Sponsor
- University of California, San Francisco